2. Academic Validation
  3. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma

Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma

  • Autophagy. 2022 Sep 7;1-15. doi: 10.1080/15548627.2022.2117893.
Jiaomeng Pan 1,  Mao Zhang 1,  Liangqing Dong 1,  Shuyi Ji 2,  Juan Zhang 1,  Shu Zhang 1,  Youpei Lin 1,  Xiaoying Wang 1,  Zhenbin Ding 1,  Shuangjian Qiu 1,  Daming Gao 3,  Jian Zhou 1,  Jia Fan 1 4 5,  Qiang Gao 1 4 5
Affiliations

Affiliations

  • 1 Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China.
  • 2 Center for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
  • 3 State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.
  • 4 Institute of Biomedical Sciences, Fudan University, Shanghai, China.
  • 5 State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China.
PMID: 36037300 DOI: 10.1080/15548627.2022.2117893
Abstract

cld-CASP3: cleaved Caspase 3; cld-PARP: cleaved PARP; DTP: drug tolerant persister; GO: Gene Ontology; GTEx: The Genotype-Tissue Expression; HCC: hepatocellular carcinoma; HCQ: hydroxychloroquine; IC50: half maximal inhibitory concentration value; KEGG: Kyoto Encyclopedia of Genes and Genomes; LAPTM5: lysosomal protein transmembrane 5; NT: non-targeting; PDC: patient-derived primary cell lines; PDO: patient-derived primary organoid; TCGA: The Cancer Genome Atlas.

Keywords

Autophagy; LAPTM5; drug resistance; lenvatinib; liver cancer; whole-genome CRISPR-Cas9 screen.

Figures
Products